Search Results - "Bernett, J"

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy by Yadav, Rajbharan, Schubbert, Suzanne, Holder, Patrick G, Chiang, Eugene Y, Kiabi, Nargess, Bogaert, Liz, Leung, Irene, Rashid, Rumana, Avery, Kendra N, Bonzon, Christine, Desjarlais, John R, Sanjabi, Shomyseh, Sharma, Amy, Lepherd, Michelle, Shelton, Amy, Chan, Pam, Liu, Yanqiu, Joslyn, Louis, Hosseini, Iraj, Stefanich, Eric G, Kamath, Amrita V, Bernett, Matthew J, Shivva, Vittal

“…Interleukin 15 (IL-15) is a potential anticancer agent and numerous engineered IL-15 agonists are currently under clinical investigation. Selective targeting…”
Get full text

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies by Horton, Holly M., Bernett, Matthew J., Peipp, Matthias, Pong, Erik, Karki, Sher, Chu, Seung Y., Richards, John O., Chen, Hsing, Repp, Roland, Desjarlais, John R., Zhukovsky, Eugene A.

“…CD40 is highly expressed on various B-lineage malignancies and represents an attractive immunotherapy target for neoplastic disease. Previous work showed that…”
Get full text

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody by Chu, Seung Y., PhD, Horton, Holly M., PhD, Pong, Erik, MS, Leung, Irene W.L., PhD, Chen, Hsing, MS, Nguyen, Duc-Hanh, BS, Bautista, Cristina, BS, Muchhal, Umesh S., PhD, Bernett, Matthew J., PhD, Moore, Gregory L., PhD, Szymkowski, David E., PhD, Desjarlais, John R., PhD

“…Background Sequestration of IgE to prevent its binding to high-affinity IgE receptor FcϵRI on basophils and mast cells is an effective therapy for allergic…”
Get full text

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function by Tai, Yu-Tzu, Horton, Holly M., Kong, Sun-Young, Pong, Erik, Chen, Hsing, Cemerski, Saso, Bernett, Matthew J., Nguyen, Duc-Hanh T., Karki, Sher, Chu, Seung Y., Lazar, Greg A., Munshi, Nikhil C., Desjarlais, John R., Anderson, Kenneth C., Muchhal, Umesh S.

“…HM1.24, an immunologic target for multiple myeloma (MM) cells, has not been effectively targeted with therapeutic monoclonal antibodies (mAbs). In this study,…”
Get full text

Crystal Structure and Biochemical Characterization of Human Kallikrein 6 Reveals That a Trypsin-like Kallikrein Is Expressed in the Central Nervous System by Bernett, Matthew J., Blaber, Sachiko I., Scarisbrick, Isobel A., Dhanarajan, Pushparani, Thompson, Steven M., Blaber, Michael

“…The human kallikreins are a large multigene family of closely related serine-type proteases. In this regard, they are similar to the multigene kallikrein…”
Get full text

Abstract 5549: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity by Varma, Rajat, Liu, Ke, Bonzon, Christine, Rashid, Rumana, Rodriguez, Nicole, Hassanzadeh-Kiabi, Nargess, Ardila, Connie, Chu, Seung Y., Muchhal, Umesh S., Desjarlais, John R., Bernett, Matthew J.

“…Abstract Interleukin-12 (IL12) is a proinflammatory cytokine produced by activated antigen-presenting cells that induces differentiation of Th1 cells and…”
Get full text

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release by Zuch de Zafra, Christina L, Fajardo, Flordeliza, Zhong, Wendy, Bernett, Matthew J, Muchhal, Umesh S, Moore, Gregory L, Stevens, Jennitte, Case, Ryan, Pearson, Joshua T, Liu, Siyuan, McElroy, Patricia L, Canon, Jude, Desjarlais, John R, Coxon, Angela, Balazs, Mercedesz, Nolan-Stevaux, Olivier

“…Despite advances in the treatment of multiple myeloma, new therapies are needed to induce more profound clinical responses. T-cell-redirected lysis triggered…”
Get full text

IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell Expansion by Li, Ji, Clark, Robyn, Slaga, Dionysos, Avery, Kendra, Liu, Ke, Schubbert, Suzanne, Varma, Rajat, Chiang, Eugene, Totpal, Klara, Bernett, Matthew J, Holder, Patrick G, Junttila, Teemu T

“…An insufficient quantity of functional T cells is a likely factor limiting the clinical activity of T-cell bispecific antibodies, especially in solid tumor…”
Get more information

Enzymatic Properties of Rat Myelencephalon-Specific Protease by Blaber, Sachiko I, Scarisbrick, Isobel A, Bernett, Matthew J, Dhanarajan, Pushparani, Seavy, Margaret A, Jin, Yonghao, Schwartz, Martin A, Rodriguez, Moses, Blaber, Michael

“…Myelencephalon-specific protease (MSP), first identified in the rat and now known to have a human homologue (human kallikrein 6), is preferentially expressed…”
Get full text

Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease by Blaber, Sachiko I., Ciric, Bogoljub, Christophi, Geroge P., Bernett, Matthew J., Blaber, Michael, Rodriguez, Moses, Scarisbrick, Isobel A.

“…ABSTRACT Kallikrein 6 (K6, MSP) is a newly identified member of the Kallikrein family of serine proteases that is preferentially expressed in the adult central…”
Get full text

1193 Synergistic targeting of multiple activating pathways with natural killer cell engagers by Zhang, Tian, Faber, Matthew S, Pong, Erik, Liu, Ke, Kim, Nahee, Bernett, Matthew J, Bonzon, Christine, Wieler, James, Diaz, Juan E, Avery, Kendra N, Henderson, Elizabeth, Yeh, William Y, Qi, Jing, Hao, Su-Shin, Rashid, Rumana, Bahjat, Rena, Desjarlais, John R, Bykova, Katrina

“…BackgroundTumor microenvironment induced antigens present a unique opportunity to effectively target diseased tissue over normal and to modulate the immune…”
Get full text

A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats by Moore, Gregory L., Bernett, Matthew J., Rashid, Rumana, Pong, Erik W., Nguyen, Duc-Hanh T., Jacinto, Jonathan, Eivazi, Araz, Nisthal, Alex, Diaz, Juan E., Chu, Seung Y., Muchhal, Umesh S., Desjarlais, John R.

“…•A novel heterodimeric Fc platform for creating bispecific antibodies is presented.•Heterodimer yields over 95% are achieved with little change in Fc…”
Get full text

An atomic resolution structure for human fibroblast growth factor 1 by Bernett, Matthew J., Somasundaram, Thayumanasamy, Blaber, Michael

“…A 1.10‐Å atomic resolution X‐ray structure of human fibroblast growth factor 1 (FGF‐1), a member of the β‐trefoil superfold, has been determined. The β‐trefoil…”
Get full text

AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer by Nolan-Stevaux, Olivier, Li, Cong, Liang, Lingming, Zhan, Jinghui, Estrada, Juan, Osgood, Tao, Li, Fei, Zhang, Hanzhi, Case, Ryan, Murawsky, Christopher M, Estes, Bram, Moore, Gregory L, Bernett, Matthew J, Muchhal, Umesh, Desjarlais, John R, Staley, Binnaz K, Stevens, Jennitte, Cooke, Keegan S, Aeffner, Famke, Thomas, Oliver, Stieglmaier, Julia, Lee, Jae-Lyun, Coxon, Angela, Bailis, Julie M

“…The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in most prostate tumors and at increased levels in metastatic…”
Get more information

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia by HORTON, Holly M, BERNETT, Matthew J, DESJARLAIS, John R, ZHUKOVSKY, Eugene A, PONG, Erik, PEIPP, Matthias, KARKI, Sher, CHU, Seung Y, RICHARDS, John O, VOSTIAR, Igor, JOYCE, Patrick F, REPP, Roland

“…CD19 is a pan B-cell surface receptor expressed from pro-B-cell development until its down-regulation during terminal differentiation into plasma cells. CD19…”
Get full text

Deep proteome profiling of reticulated platelets in patients with chronic coronary syndrome using mass cytometry by Han, J, Kirmes, K, Klug, M, Bernett, J, Manz, Q, Arend, L, Lazareva, O, Rosenbaum, M, Ruland, J, Laugwitz, K L, List, M, Bernlochner, I, Bongiovanni, D

“…Abstract Funding Acknowledgements Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Else Körner Fresenius Stiftung…”
Get full text

Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease by Blaber, Sachiko I., Ciric, Bogoljub, Christophi, Geroge P., Bernett, Matthew J., Blaber, Michael, Rodriguez, Moses, Scarisbrick, Isobel A.

Get full text

Abstract 5000: Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target-mediated T cell activation in monkeys: A potential therapy for prostate cancer by Chu, Seung Y., Pong, Erik W. K., Rashid, Rumana, Chen, Hsing, Chan, Emily W., Phung, Sheryl, Endo, Nancy A., Ardila, Maria C., Bonzon, Christine, Leung, Irene W. L., Muchhal, Umesh S., Moore, Gregory L., Bernett, Matthew J., Desjarlais, John R., Szymkowski, David E.

“…Abstract PSMA (Prostate-Specific Membrane Antigen) is a promising therapeutic target in prostate cancer. Exploiting the high and selective expression of PSMA…”
Get full text

Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions by Bernett, Matthew J., Karki, Sher, Moore, Gregory L., Leung, Irene W.L., Chen, Hsing, Pong, Erik, Nguyen, Duc-Hanh T., Jacinto, Jonathan, Zalevsky, Jonathan, Muchhal, Umesh S., Desjarlais, John R., Lazar, Greg A.

“…Fully human monoclonal antibodies (mAbs) derived from transgenic mice or human antibody libraries are the current state of the art for reducing the…”
Get full text

Immune suppression in cynomolgus monkeys by XPro9523: An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn by Bernett, Matthew J., Chu, Seung Y., Leung, Irene, Moore, Gregory L., Lee, Sung-Hyung, Pong, Erik, Chen, Hsing, Phung, Sheryl, Muchhal, Umesh S., Horton, Holly M., Lazar, Greg A., Desjarlais, John R, Szymkowski, David E.

“…The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant,…”
Get full text